These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 12469940)
1. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Henry SP; Beattie G; Yeh G; Chappel A; Giclas P; Mortari A; Jagels MA; Kornbrust DJ; Levin AA Int Immunopharmacol; 2002 Nov; 2(12):1657-66. PubMed ID: 12469940 [TBL] [Abstract][Full Text] [Related]
2. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. Henry SP; Giclas PC; Leeds J; Pangburn M; Auletta C; Levin AA; Kornbrust DJ J Pharmacol Exp Ther; 1997 May; 281(2):810-6. PubMed ID: 9152389 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Henry SP; Jagels MA; Hugli TE; Manalili S; Geary RS; Giclas PC; Levin AA Nucleic Acid Ther; 2014 Oct; 24(5):326-35. PubMed ID: 25093529 [TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140 [TBL] [Abstract][Full Text] [Related]
5. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591 [TBL] [Abstract][Full Text] [Related]
6. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Henry SP; Templin MV; Gillett N; Rojko J; Levin AA Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680 [TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555 [TBL] [Abstract][Full Text] [Related]
15. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Henry SP; Bolte H; Auletta C; Kornbrust DJ Toxicology; 1997 Jun; 120(2):145-55. PubMed ID: 9184201 [TBL] [Abstract][Full Text] [Related]
17. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Bijsterbosch MK; Rump ET; De Vrueh RL; Dorland R; van Veghel R; Tivel KL; Biessen EA; van Berkel TJ; Manoharan M Nucleic Acids Res; 2000 Jul; 28(14):2717-25. PubMed ID: 10908328 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Henry SP; Taylor J; Midgley L; Levin AA; Kornbrust DJ Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):473-81. PubMed ID: 9361906 [TBL] [Abstract][Full Text] [Related]
19. Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. Henry SP; Denny KH; Templin MV; Yu RZ; Levin AA Birth Defects Res B Dev Reprod Toxicol; 2004 Dec; 71(6):368-73. PubMed ID: 15617022 [TBL] [Abstract][Full Text] [Related]
20. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Advani R; Lum BL; Fisher GA; Halsey J; Geary RS; Holmlund JT; Kwoh TJ; Dorr FA; Sikic BI Invest New Drugs; 2005 Oct; 23(5):467-77. PubMed ID: 16133798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]